Format

Send to

Choose Destination
Oncotarget. 2016 Feb 9;7(6):6566-75. doi: 10.18632/oncotarget.6512.

SLC7A5 act as a potential leukemic transformation target gene in myelodysplastic syndrome.

Author information

1
Department of Hematology, Huashan Hospital, Fudan University, Shanghai, 200040, China.

Abstract

OBJECTIVE:

Myelodysplastic syndromes (MDS) are a heterogenous group of clonal hematopoietic stem cell disorders characterized by increased risk of leukemic transformation. This study identifies microRNAs(miRNA) and miRNA targets that might represent leukemic transformation markers for MDS.

METHODS:

Based on our previously established nested case-control study cohort of MDS patients, we chose paired patients to undergo Angilent 8 × 15K human miRNA microarrays. Target prediction analysis was administrated using targetscan 5.1 software. We further investigated the function of target gene in MDS cell line using siRNA method, including cell proliferation, cell apoptosis, cell cycle and electron microscope.

RESULTS:

Finally we screened a subset of 7 miRNAs to be significantly differentially expressed between the case (at the end of follow up with leukemic transformation) and control group (at the end of follow up without leukemic transformation). Target prediction analysis revealed SLC7A5 was the common target gene of these 7 miRNAs. Further study on the function of SLC7A5 gene in SKM-1 cell line showed that downregulation of SLC7A5 inhibited SKM-1 cells proliferation, increased apoptosis and caused cell cycle arrest in the G0/G1 stage.

CONCLUSIONS:

Our data indicate that SLC7A5 gene may act as a potential leukemic transformation target gene in MDS.

KEYWORDS:

SKM-1 cell line; SLC7A5 gene; miRNA; myelodysplastic syndrome; siRNA

PMID:
26657287
PMCID:
PMC4872733
DOI:
10.18632/oncotarget.6512
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center